Alirocumab's Price Reduction

Sanket S Dhruva; Joseph S Ross; Nihar R Desai

doi:10.1161/CIRCULATIONAHA.118.036069

Alirocumab's Price Reduction

Circulation. 2018 Oct 9;138(15):1502-1504. doi: 10.1161/CIRCULATIONAHA.118.036069.

Authors

Sanket S Dhruva^{1

2}, Joseph S Ross^{1

3

4

5}, Nihar R Desai^{6

5}

Affiliations

¹ National Clinician Scholars Program (S.S.D., J.S.R.), Yale University, New Haven, CT.
² Veterans Affairs Connecticut Healthcare System, West Haven (S.S.D.).
³ Section of General Internal Medicine (J.S.R.), Yale University, New Haven, CT.
⁴ Department of Internal Medicine, Yale School of Medicine, and Department of Health Policy and Management, Yale School of Public Health (J.S.R.), Yale University, New Haven, CT.
⁵ Center for Outcomes Research and Evaluation, Yale New Haven Hospital, CT (J.S.R., N.R.D.).
⁶ Section of Cardiovascular Medicine (N.R.D.), Yale University, New Haven, CT.

PMID: 30354510
DOI: 10.1161/CIRCULATIONAHA.118.036069

No abstract available

Keywords: cardiovascular diseases; cost-benefit analysis; costs and cost analysis; insurance, health, reimbursement; outcome and process assessment (health care).

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antibodies, Monoclonal / economics*
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents / economics*
Commerce / economics*
Cost-Benefit Analysis
Drug Costs*
Drug Industry / economics*
Health Services Accessibility / economics*
Humans

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
alirocumab